Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Core Insights - Eledon Pharmaceuticals has achieved significant clinical milestones for its lead product, tegoprubart, in the field of transplantation, particularly in kidney and islet cell transplants [2][5] - The company completed enrollment in the Phase 2 BESTOW trial ahead of schedule and is on track to report topline results in Q4 2025 [1][5] - Positive initial data from an investigator-initiated trial at UChicago Medicine indicates potential insulin independence in type 1 diabetes patients treated with tegoprubart [5] 2024 Key Highlights - Enrollment of 120 patients in the Phase 2 BESTOW trial was completed approximately four months earlier than planned [5] - Updated data from a Phase 1b trial showed tegoprubart to be generally safe and well tolerated, with a mean estimated glomerular filtration rate (eGFR) of 70.5 mL/min/1.73m post-transplant [5] - Initial data from three islet transplant recipients indicated potential insulin independence without the use of tacrolimus, the current standard of care [5] Anticipated 2025 Milestones - Summer 2025: Updated interim clinical data from ongoing Phase 1b and long-term efficacy studies of tegoprubart in kidney transplantation will be reported [5] - Q4 2025: Topline results from the Phase 2 BESTOW trial will be announced [5] - 2025: Longer-term follow-up results from the investigator-led trial at UChicago Medicine for pancreatic islet transplantation will be provided [5] Financial Overview - Eledon completed two financings totaling $135 million in gross proceeds, expected to support operations through the end of 2026 [1][5]